Evidence map›Paper›PMID 42234191›Full record

ArticleMikrochimica acta2026

In situ nanozyme assembly amplification enables sub-femtomolar-level colorimetric immunoassay.

Xiang Peng, Mingming Lin, Rui Zhou, Shuqi Li, Yongfeng Tan, Wenke Chen, Zhuangqiang Gao

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiang PengMarshall Laboratory of Biomedical Engineering, Shenzhen Key Laboratory for Nano-Biosensing Technology, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, People's Republic of China.
Mingming LinJingyang Town Health Center, Fuqing, Fuzhou, Fujian, 350304, People's Republic of China.
Rui ZhouMarshall Laboratory of Biomedical Engineering, Shenzhen Key Laboratory for Nano-Biosensing Technology, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, People's Republic of China.
Shuqi LiMarshall Laboratory of Biomedical Engineering, Shenzhen Key Laboratory for Nano-Biosensing Technology, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, People's Republic of China.
Yongfeng TanMarshall Laboratory of Biomedical Engineering, Shenzhen Key Laboratory for Nano-Biosensing Technology, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, People's Republic of China.
Wenke ChenDepartment of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, People's Republic of China.
Zhuangqiang GaoMarshall Laboratory of Biomedical Engineering, Shenzhen Key Laboratory for Nano-Biosensing Technology, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, People's Republic of China. zhuangqiang.gao@szu.edu.cn.

Funding

National Key Research and Development Program of China 2023YFA0915700National Natural Science Foundation of China 22304122Science, Technology and Innovation Commission of Shenzhen Municipality KQTD20221101093605019
6 · The paper itself

Abstract

An in situ nanozyme assembly amplification strategy is reported based on the programmable bioaffinity-driven assembly of streptavidin-Pd@Pt and biotin-Pd@Pt nanozymes, enabling ultrasensitive colorimetric immunoassay of protein biomarkers at sub-femtomolar levels. In this design, streptavidin-Pd@Pt nanozymes are first anchored onto the immunocomplexes through standard biotinylated antibody recognition, followed by the recruitment of biotin-Pd@Pt nanozymes via strong streptavidin-biotin interactions. This stepwise and localized assembly process induces the formation of high-density Pd@Pt nanozyme clusters directly on the target recognition sites, dramatically increasing the local nanozyme concentration and catalytic accessibility. Benefiting from the exceptional peroxidase-like catalytic activity of the precisely engineered Pd@Pt nanozymes, together with the assembly-induced signal multiplication effect, the resulting nanozyme assemblies generate substantially amplified colorimetric signals. As a proof of concept, the proposed immunoassay enables quantitative detection of interleukin-10 (IL-10, selected as a model protein biomarker) with a detection limit as low as 10 fg mL

Indexed as

ColorimetryInterleukin-10Metal NanoparticlesBiotinCatalysisHumansImmunoassayLimit of DetectionPalladiumPlatinumStreptavidinBiotinInterleukin-10PalladiumPlatinumStreptavidinColorimetric detectionNanozyme assembly amplificationPd@Pt nanozymesProtein biomarkersSub-femtomolar sensitivity

Identifiers

PMID42234191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.